Results 271 to 280 of about 152,115 (284)

Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer

New England Journal of Medicine, 2006
Robert Gray, Afshin Dowlati
exaly  

Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer

New England Journal of Medicine, 2011
Michael A Bookman, Bradley J Monk
exaly  

Bevacizumab—has it reached its final resting place?

Nature Reviews Clinical Oncology, 2011
David J Kerr
exaly  

Paclitaxel plus Bevacizumab versus Paclitaxel Alone for Metastatic Breast Cancer

New England Journal of Medicine, 2007
Maura Dickler, Nancy E Davidson
exaly  

Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer

New England Journal of Medicine, 2004
Jordan D Berlin, Napoleone Ferrara
exaly  

Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)

Lancet, The, 2017
Krishnansu S Tewari, Ana Oaknin, Michael J Birrer   +2 more
exaly  

Aflibercept, Bevacizumab, or Ranibizumab for Diabetic Macular Edema

New England Journal of Medicine, 2015
Lee M Jampol, Michael J Elman, Jennifer K Sun   +2 more
exaly  

Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): a multicentre, open-label, phase 3, randomised controlled trial

Lancet, The, 2019
Brian I Rini, Thomas Powles, Michael B Atkins   +2 more
exaly  

Bevacizumab

Reactions Weekly, 2007
openaire   +1 more source

Further delineating bevacizumab's response spectrum

Nature Reviews Clinical Oncology, 2014
David A Reardon
exaly